ALK testing

The non-small cell lung cancer drug now has two FDA-approved companion tests, Abbott's FISH test and Ventana's IHC test, for identifying patients most likely to benefit from treatment.

The partners will offer Horizon Discovery's reference materials as a standalone product to help validate ArcherDx's ALK fusion assays.

Ventana is providing ALK testing for clinical trials studying both Novartis' Zykadia and Genentech's alectinib.

Pfizer's Xalkori yielded significantly longer progression-free survival than standard chemotherapy in the Phase III trial of first-line treatment of ALK-positive NSCLC.

The company launched a blood-based diagnostic to guide treatment strategies for lung cancer patients with ALK fusions who don't have sufficient tumor biopsy material for analysis by tissue-based tests.

A group of researchers from Germany's Robert Bosch Hospital and other associated institutions have described a PCR-based method they have developed to detect ALK fusions that takes advantage of some aspects of a method published earlier this year by Pfizer researchers, but which they say could be

A Pfizer research group, working with Seoul's Samsung Medical Center, has published a study demonstrating a multiplex method for detecting ALK, ROS1, and RET fusions in a single assay.

Originally published April 9.

Boehringer Ingelheim has launched a campaign to educate healthcare providers about biomarker testing to personalize treatment for non-small cell lung cancer patients.

This article has been updated to correct the name of the Phase I extension trial to Study 1001. Originally published June 3.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.